Form D · Biotechnology

JUVA LIFE INC./Canada

Vancouver, A1 · CIK 0001778651

Offering snapshot reported Feb 26, 2021 · SEC filing

Reported sold: $208K
Investors reported: 1
Minimum accepted: $19.7K
First sale: Feb 18, 2021

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Feb 26, 2021	Initial	$207,500	No comparison	1	SEC filing
Dec 23, 2019	Initial	$50,914	No comparison	1	SEC filing
Jul 24, 2019	Initial	$74,397	No comparison	4	SEC filing

Offering details

Securities: Option to acquire, Security to be acquired, Other
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-390648

Special Warrants (250,000 x $0.83|C$1.05), convertible without further payment into common shares and warrants, plus the exercise price of the warrants (125,000 x $1.06|C$1.35). There is no assurance the warrants, exp. Feb 18, 2023, will be exercised.

Each Special Warrant will automatically convert to units upon the earlier of receipt of a final prospectus receipt qualifying the distribution of the units or June 19, 2021.

Source: Form D, filed Feb 26, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Douglas Chloupek	Director, Executive
Kari Gothie	Director, Executive
Mathew Lee	Executive
Thomas Leschak	Director
Rakesh Patel	Director
Neil Ruditsky	Executive
Norton Singhavon	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1400 885 West Georgia Street
Vancouver, A1, V6C 3E8